Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch Study of Emtricitabine/Tenofovir Alafenamide (F/TAF) in Virologically Suppressed HIV-1 Infected Children and Adolescents
2015-001339-19Phase 2
- Sponsor
- Gilead Sciences
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emtricitabine + tenofovir alafenamide in Human immunodeficiency virus infection type 1, sponsored by Gilead Sciences. Primary endpoint: AUCtau for tenofovir alafenamide.
02
Drugs
emtricitabine + tenofovir alafenamide
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2015-001339-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001339-19.